BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

2015 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/14/15BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
12/03/15BioLineRx Establishes Oncology Scientific Advisory BoardPrinter Friendly Version
11/25/15BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015Printer Friendly Version
11/24/15BioLineRx to Present at the LD Micro Main EventPrinter Friendly Version
11/23/15BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure ConditionsPrinter Friendly Version
11/16/15BioLineRx Reports Third Quarter 2015 Financial ResultsPrinter Friendly Version
11/09/15BioLineRx to Report Third Quarter 2015 Results on November 16, 2015Printer Friendly Version
11/05/15BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AMLPrinter Friendly Version
09/10/15BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic AnemiaPrinter Friendly Version
09/09/15BioLineRx’s Novel Treatment for Non-Surgical Removal of Skin Lesions Submitted for CE Mark RegistrationPrinter Friendly Version
09/03/15BioLineRx to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New YorkPrinter Friendly Version
08/20/15BioLineRx Reports Second Quarter 2015 Financial ResultsPrinter Friendly Version
08/17/15BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation TreatmentPrinter Friendly Version
08/13/15BioLineRx to Report Second Quarter 2015 Results on August 20, 2015Printer Friendly Version
07/27/15BioLineRx Announces Top-Line Results from Bellerophon’s PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BL-1040)Printer Friendly Version
06/17/15BioLineRx to Present Successful Results of Phase 1/2 Study for Novel Celiac Treatment at International Celiac Disease SymposiumPrinter Friendly Version
06/16/15BioLineRx to Present at the JMP Securities Life Sciences Conference in New YorkPrinter Friendly Version
06/15/15BioLineRx Presents Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association ConferencePrinter Friendly Version
06/03/15Research Underlying BioLineRx’s Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation AwardPrinter Friendly Version
06/01/15BioLineRx Announces Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin LesionsPrinter Friendly Version
05/27/15BioLineRx to Present Positive Safety and Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at the European Hematology Annual CongressPrinter Friendly Version
05/18/15BioLineRx Reports First Quarter 2015 Financial ResultsPrinter Friendly Version
05/11/15BioLineRx to Report First Quarter 2015 Results on May 18, 2015Printer Friendly Version
05/04/15BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid LeukemiaPrinter Friendly Version
03/25/15BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
03/23/15BioLineRx Reports Year End 2014 Financial ResultsPrinter Friendly Version
03/17/15BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015Printer Friendly Version
03/11/15BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
03/11/15BioLineRx’s Treatment for Type 1 Diabetes Effective in Preclinical TrialsPrinter Friendly Version
03/06/15BioLineRx to Present at the Annual Roth Conference in CaliforniaPrinter Friendly Version
03/06/15BioLineRx Prices $25 Million Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
03/05/15BioLineRx Announces Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
03/02/15BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation TreatmentPrinter Friendly Version
02/03/15BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10Printer Friendly Version
01/14/15BioLineRx Announces Completion of Enrollment in CE Mark Registration Trial of BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial InfarctionPrinter Friendly Version
01/06/15BioLineRx Completes Dose Escalation Stage of Phase 1 Trial for Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
01/06/15BioLineRx to Present at Biotech Showcase 2015 Conference in San FranciscoPrinter Friendly Version


Interview with Philip Serlin, CEO
December 2016